*INVITE* KOL Dinner @ IRSF: Comparing TSHA & NGNE Rett Gene Therapy Programs

Research evidence excerpt

*INVITE* KOL Dinner @ IRSF: Comparing TSHA & NGNE Rett Gene Therapy Programs

USA | Biotechnology

Taysha Gene Therapies EquityJuneResearch26, 2026

FLASH NOTE*INVITE* KOL Dinner @ IRSF: Comparing TSHA

RATING BUY& NGNE Rett Gene Therapy Programs

PRICE $6.21^

Please join us for a group dinner with Dr. David Lieberman, MD, PhD, Director

PRICE TARGET | % TO PT $13.00 | +109%

of the Rett Syndrome Program at Boston Children’s Hospital, on Monday, June

52W HIGH-LOW $7.30 - $2.25

29, at 7:00 PM CT. Discussion will focus on TSHA’s REVEAL Part A data (here)

FLOAT (%) | ADV MM (USD) 81.7% | 17.78

vs NGNE’s ph.I/II interim update (poster #65 June 29 @5PM CT), and how

to compare+contrast the two programs, ongoing pivotals (TSHA 6mo interim MARKET CAP $1.7B

1H27; NGNE data 2H27), and commercial implications. TICKER TSHA ^Prior trading day's closing price unless otherwise

noted.

Event Details:

KOL: Dr. David Lieberman, MD, PhD, Director of the Comprehensive Rett Syndrome Program at

Boston Children’s Hospital (Rett Center of Excellence) and Instructor of Neurology, Harvard Medical

School

Host: James Stamos, PhD, Jefferies

Monday June 29, 2026

7:00 PM CT

In Person Group Dinner

**Please reach out to your Jefferies Sales Rep to register**

Relevant Tickers: TSHA, NGNE, ACAD

Biography:

David Lieberman, MD, PhD, is a child neurologist at Boston Children’s Hospital and Instructor

of Neurology at Harvard Medical School. Dr. Lieberman completed his medical and doctorate

degrees in Neuroscience at Stanford University School of Medicine. He completed an internship in

Pediatrics and residency in Pediatric Neurology at Johns Hopkins University School of Medicine,

where he remained as faculty for several years before taking a faculty position in the Neurosciences

Department at UC San Diego. Dr.